Stock listing
Arrivent Biopharma, Inc.
Selected listing: AVBP · NASDAQ · USD · US
Arrivent Biopharma, Inc. (NASDAQ:AVBP), Health Technology. Latest release Oct 6, 2026: ArriVent Announces Program Update from the Phase 3 FURVENT Trial…
- Ticker
- NASDAQ:AVBP
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Other
- Exchange
- NASDAQ
- Currency
- USD
About Arrivent Biopharma, Inc.
Arrivent Biopharma, Inc. is a public company traded under the ticker AVBP in the American market. Arrivent focuses on developing innovative biopharmaceutical solutions to address unmet medical needs.
Latest news from Arrivent Biopharma, Inc.
ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
October 6, 2026
ArriVent BioPharma Reports Second Quarter 2026 Financial Results
August 12, 2026
ArriVent BioPharma Reports First Quarter 2026 Financial Results
May 10, 2026
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers
May 7, 2026
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting
March 17, 2026
Research Arrivent Biopharma, Inc.
Arrivent Biopharma, Inc. company profile
View the public company page for Arrivent Biopharma, Inc. on 6ix.
Arrivent Biopharma, Inc. news
Read company news and market updates connected to Arrivent Biopharma, Inc..
Arrivent Biopharma, Inc. investor events
Find investor webinars, events, and replay context for Arrivent Biopharma, Inc..